We at Vista Partners are excited about attending the 2nd Annual Sickle Cell Disease Therapeutics Conference on September 19th, 2013 at the Four Seasons Hotel in New York City (Cosmopolitan Suite) along with a large number of other institutional investors, pharmaceutical & biotech industry leaders, physicians, financial analysts, writers, etc. that are interested in finding ways to better understand the latest pipeline and issues around treating sickle cell disease and to create more awareness.
San Diego, CA based biopharmaceutical company, Mast Therapeutics, Inc. (NYSE MKT: MSTX), which is enrolling subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease will be hosting the conference which will be intended to serve as a forum to raise awareness for sickle cell disease and will include presentations from leading companies in sickle cell disease and discussions with experts regarding the latest advancements and trends in treatment. Conference sponsors include The Pierre Fabre Foundation, Canaccord Genuity, Piper Jaffray, Sheppard Mullin Richter & Hampton, LLP, Pharm-Olam International and Theradex Systems, Inc.
Six public and private companies developing new treatment options for patients with sickle cell disease, including bluebird bio (NASDAQ GS: BLUE) and Mast Therapeutics, Inc. (NYSE MKT: MSTX) will be presenting.
Conference attendees will hear from leaders in the sickle cell disease medical and advocacy communities, including:
Althea Grant, PhD, Chief of the Epidemiology and Surveillance Branch in the Division of Blood Disorders of the National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control
Wally R. Smith, MD, Professor of Medicine at Virginia Commonwealth University
Susan P. Perrine, MD, Professor, Pediatrics, Medicine, Pharmacology and Experimental Therapeutics Cancer Center; Director, Hemolgobinopathy Thalassemia Research Unit at the Boston University School of Medicine
Gary A. Gibson, President & CEO of The Martin Center Sickle Cell Initiative
Beatrice Garrette, Directrice Generale, The Pierre Fabre Foundation
Nirmish Shah, MD, Assistant Professor, Director of Sickle Cell Transition, Program, Division of Hematology, Division of Pediatric Hematology/Oncology at Duke University
Question & answer sessions will be moderated by the following healthcare analysts:
Ritu S. Baral, Managing Director, Senior Analyst, Biotechnology Equity Research, Canaccord Genuity
Edward A. Tenthoff, Managing Director and Senior Research Analyst, Piper Jaffray
“The Mast team is deeply committed to advancing the research and care of patients with sickle cell disease. Their commitment includes conducting one of the largest pivotal clinical studies in sickle cell disease crisis intervention (EPIC) with their lead product candidate MST-188, creating and hosting the Annual Sickle Cell Disease Therapeutics Conference and sponsoring and supporting sickle cell community based organizations and events across the country,” stated Brian M. Culley, Chief Executive Officer of Mast Therapeutics. “This disease was identified over one hundred years ago, but only one FDA-approved drug is available, and none are available to treat an on-going vaso-occlusive crisis or the underlying ischemia and infarction that play a role in reducing the average life expectancy to around 45 years. Awareness leads to investment, development, and eventually, to new treatments. This conference offers an excellent forum for investors and potential partners to review the latest advancements for patients suffering with this rare disease.”
More information can be found on the conference web site at www.scdconference.com.
For more information about Mast Therapeutics, Inc. (NYSE MKT: MSTX) and their work in sickle cell disease please visit a company dedicated page at the Vista Partners’ website by clicking here where you can find interesting commentary, links to SEC filings, the company’s website, related video, the latest company presentation/corporate annual report, the latest company and industry news & a FREE Vista Partners’ Research Report & more.
The post A Vista Partners Commentary “Mast Therapeutics (NYSE MKT: MSTX) Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013 IN NYC” appeared first on Vista Partners.